# Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

> **NCT01839734** · PHASE2 · COMPLETED · sponsor: **Ruth M. Rothstein CORE Center** · enrollment: 20 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Lubiprostone

## Key facts

- **NCT ID:** NCT01839734
- **Lead sponsor:** Ruth M. Rothstein CORE Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-04
- **Final completion:** 2016-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839734, "Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01839734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*